Mosapramine
![]() | |
![]() | |
| Clinical data | |
|---|---|
| Trade names | Cremin (クレミン, JP) |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral (tablets, oral solution) |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG |
|
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C28H35ClN4O |
| Molar mass | 479.07 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
Mosapramine (Cremin) is an atypical antipsychotic used in Japan.[1] It is a potent dopamine antagonist with high affinity to the D2, D3, and D4 receptors,[2] and with moderate affinity for the 5-HT2 receptors.[3]
See also
References
- ↑ Takahashi N, Terao T, Oga T, Okada M (1999). "Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia". Neuropsychobiology. 39 (2): 81–5. doi:10.1159/000026565. PMID 10072664. S2CID 6554048.
- ↑ Futamura T, Ohashi Y, Yano K, Takahashi Y, Haga K, Fukuda T (May 1996). "[The affinities of mosapramine for the dopamine receptor subtypes in human cell lines expressing D2, D3 and D4 receptors]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica. 107 (5): 247–53. doi:10.1254/fpj.107.247. PMID 8690306.
- ↑ Sumiyoshi T, Suzuki K, Sakamoto H, Yamaguchi N, Mori H, Shiba K, Yokogawa K (February 1995). "Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy". Neuropsychopharmacology. 12 (1): 57–64. doi:10.1016/0893-133X(94)00064-7. PMID 7766287.
| Typical |
|
|---|---|
| Disputed | |
| Atypical |
|
| Others |
|
| |
| Classes |
|
|---|---|
| Antidepressants (TCAs and TeCAs) |
|
| Antihistamines |
|
| Antipsychotics |
|
| Anticonvulsants | |
| Others |
|
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

